{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T19:31:18Z","timestamp":1769196678959,"version":"3.49.0"},"reference-count":9,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Neurol"],"published-print":{"date-parts":[[2009]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; The effects of interferon-\u03b2&lt;sub&gt;1b&lt;\/sub&gt; (IFN-\u03b2&lt;sub&gt;1b&lt;\/sub&gt;) administration in multiple sclerosis (MS) patients have been confirmed, however, those in neuromyelitis optica (NMO) patients have not been shown. In this study, we assessed the effects of IFN-\u03b2&lt;sub&gt;1b&lt;\/sub&gt; treatment on disease exacerbation and disability progression in MS or NMO patients. &lt;i&gt;Methods:&lt;\/i&gt; We reviewed a series of 104 consecutive patients with relapsing-remitting MS (RRMS) (69) or NMO (35) treated with IFN-\u03b2&lt;sub&gt;1b&lt;\/sub&gt; in the MS clinical center of a national hospital in Japan. &lt;i&gt;Results:&lt;\/i&gt; The relapse number in the RRMS patients significantly decreased within 1 year after IFN-\u03b2&lt;sub&gt;1b&lt;\/sub&gt; treatment (p &lt; 0.00001); however, that in the NMO patients did not show a significant decrease (p = 0.5601). The decrease in annualized relapse rates in each RRMS patient after treatment was significant (p &lt; 0.01), but that in each NMO patient was not (p &gt; 0.05). The change in Kurtzke\u2019s Expanded Disability Status Scale score 1 year after treatment was higher in the NMO patients than in the RRMS patients (p = 0.0225). &lt;i&gt;Conclusion:&lt;\/i&gt; In NMO patients, IFN-\u03b2&lt;sub&gt;1b&lt;\/sub&gt; treatment was not effective in reducing the relapse number and the disability progression.<\/jats:p>","DOI":"10.1159\/000227277","type":"journal-article","created":{"date-parts":[[2009,7,7]],"date-time":"2009-07-07T14:59:48Z","timestamp":1246978788000},"page":"167-170","source":"Crossref","is-referenced-by-count":65,"title":["Interferon-\u03b2&lt;sub&gt;1b&lt;\/sub&gt; Treatment in Neuromyelitis Optica"],"prefix":"10.1159","volume":"62","author":[{"given":"Masami","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Komori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,7,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212%2F01.wnl.0000237641.33768.8d"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097%2FWCO.0b013e32814f1c6b"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177%2F1352458506070732"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002%2Fana.1032"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212%2F01.wnl.0000216139.44259.74"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177%2F1352458507076976"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136%2Fjnnp.2006.114165"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00415-006-0400-z"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093%2Fbrain%2Fawm027"}],"container-title":["European Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/227277","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/227277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T21:27:34Z","timestamp":1745443654000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000227277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":9,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,8,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000227277","archive":["Portico"],"relation":{},"ISSN":["0014-3022","1421-9913"],"issn-type":[{"value":"0014-3022","type":"print"},{"value":"1421-9913","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009]]}}}